However, the therapeutic potential of mPGES1 inhibitors to reverse PGE2-mediated monocyte dysfunction in decompensated cirrhosis appears limited, with no drug targeting this pathway progressing beyond safety studies. Here, PTGES is linked to Cirrhosis.